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Background: The incidence and clinical characteristics of adverse pulmonary reactions result-
ing from anticancer monoclonal antibody (mAbs) therapy have not been well described. We
determined the incidence and clinical characteristics of adverse pulmonary reactions in
patients treated with anticancer chemotherapy including mAbs.
Methods: A retrospective cohort study was performed including patients who were treated
with a chemotherapeutic regimen that included rituximab, trastuzumab, cetuximab, or beva-
cizumab at Seoul National University Hospital between January 1, 2004 and December 31,
2008. Rates of adverse pulmonary reactions classified as non-infectious and infectious compli-
cations were compared with those among patients treated with comparable regimens without
mAbs.
Results: In total, 1078 patients were included (418 for rituximab, 329 for trastuzumab, 122 for
cetuximab, 209 for bevacizumab). Adverse pulmonary reactions were identified in 36 patients
(3.5%) and the incidence differed among agents: cetuximab (9%), rituximab (5.3%), trastuzu-
mab (0.6%), bevacizumab (0.5%). Infectious pulmonary complications occurred in 28 patients,
and eight patients experienced non-infectious pulmonary complications, most commonly inter-
stitial lung disease (6 patients). In a multivariate analysis, low serum albumin level was asso-
ciated with the development of pulmonary complications. The incidence of overall adverse
pulmonary reactions did not differ between the mAbs users and the 1012 patients treated with
comparable regimens other than mAbs (3.5% vs. 2.8%, PZ 0.53).th factor receptor; ILD, interstitial lung disease; NHL, non-Hodgkin’s lymphoma; mAbs, monoclonal
l growth factor.
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444 H.J. Kang et al.Conclusions: Infectious and non-infectious adverse pulmonary reactions occur in patients with
cancer who are administered a regimen including mAbs. Clinicians should be alert for the possi-
bility of pulmonary adverse reactions, particularly among patientswith low serumalbumin levels.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
New anti-neoplastic agents are constantly being added to the
list of available treatments for various cancers.1,2 Among
them, biological agents are one of the most promising
modalities to combat cancers and other diseases.3 In fact,
more than 20% of the compounds approved by United States
regulatory authorities over the last 5 years were biological
agents.4 Representative newanti-neoplastic biological agents
are monoclonal antibodies (mAbs), which bind specifically to
target cells. By blocking specific cell receptors, mAb therapy
destroys malignant tumor cells and prevents tumor growth.5
For example, rituximab, which targets the CD20
receptor, is widely used for CD20þ non-Hodgkin’s lymphoma
(NHL).6 Cetuximab, which binds to the epidermal growth
factor receptor (EGFR), has shown efficacy in patients with
colorectal, head/neck, and non-small cell lung cancers.7 As
with other anticancer drugs, adverse pulmonary events
associated with mAbs can occur, including dyspnea,
pulmonary embolism, pneumonia, interstitial lung disease,
and pleural effusion.6e11
In this study, we determined the incidence and clinical
characteristics of adverse pulmonary drug reactions in
patients treated with anticancer chemotherapy including
mAbs in combination with other agents or as monotherapy.
Materials and methods
Study population
A retrospective cohort study was performed with patients
whowere treatedwith a chemotherapeutic regimen included
rituximab, trastuzumab, cetuximab, or bevacizumab at Seoul
National University Hospital between January 1, 2004 and
December 31, 2008. Patients, older than 18 years, who were
being treated for their cancer with the aforementioned
mAbs, were included. Patients lost to follow-up immediately
after the first chemotherapy session were excluded. For
comparison, patients treated with comparable regimens
without mAbs were also included: CHOP (rituximab, cyclo-
phosphamide, adriamycin, vincristine, and prednisolone)
users as counterparts of rituximab users, Taxol users as
counterparts of trastuzumab users, and FOLFOX (oxaliplatin,
leucovorin, and 5-fluorouracil) or FOLFIRI (irinotecan, leu-
covorin, and 5-fluorouracil) users as counterparts of cetux-
imab and bevacizumab users. The Ethical Review Committee
of our institution approved the protocol for this study.
Clinical data review
Patient clinical data, including medical records, radio-
graphic findings, and laboratory results were reviewed.Definition of adverse pulmonary reaction
New respiratory symptoms or abnormal radiographic/labo-
ratory results that developed after mAb use were reviewed
as possible adverse reactions. Two of the authors (HJ Kang
and JS Park) reviewed the data independently. If their
opinions on the presence of an adverse pulmonary reaction
differed, another author (JJ Yim) made the decision.
Adverse pulmonary reactions were divided into non-
infectious and infectious complications, based on
a previous study.1
Non-infectious complications
 Hypersensitivity with bronchospasm
- Defined as bronchospasm plus other hypersensitivity-
related symptoms (angioedema, rash, urticaria,
hypotension, arthralgia, nausea, vomiting, hypoten-
sion, or hypertension).
 Drug-induced interstitial lung disease
- Clinical and radiographic manifestations compatible
with interstitial pneumonitis.
➢ Clinical manifestations including dry cough, dysp-
nea, and fever.
➢ Radiographic findings such as diffuse ground-glass
opacity, reticular shadows, or consolidation
without segmental distribution and a honeycomb
pattern with no evidence of underlying heart
disease, infection, or other pulmonary disease.
 Noncardiogenic pulmonary edema.
- Diagnosed when pulmonary edema was not associ-
ated with heart failure or increased left atrial
pressure.
 Acute lung injury.
- Noncardiogenic pulmonary injury associated with
evidence of acute inflammation, such as fever and
elevated neutrophils in broncho-alveolar lavage fluid.
- Diffuse bilateral pulmonary infiltrate with no
evidence of elevated left atrial pressure and a PO2/
FiO2 ratio <300.
 Acute respiratory distress syndrome.
- Diffuse bilateral pulmonary infiltrate with no
evidence of elevated left atrial pressure and a PaO2/
FiO2 ratio <200.Infectious complications
 Symptoms of an acute lower-respiratory tract illness
(cough and at least one other lower-respiratory tract
symptom).
- New focal chest signs on examination.
Table 1 Baseline clinical characteristics of the 1078 patients used targeted chemotherapeutic agents and 1012 control patients.
Users of targeted chemotherapeutic agents Non-users of targeted chemotherapeutic agents
Total Rituximab Trastuzumab Cetuximab Bevacizumab Total CHOP users
(counterpart of
rituximab user)
Taxol users
(counterpart of
trastuzumab
user)
FOLFOX or
FOLFIRI users
(counterpart
of cetuximab /
bevacizumab
user)
Number of patients 1078 418 (38.7%) 329 (30.5%) 122 (11.3%) 209 (19.4%) 1012 123 (12.1%) 119 (11.8%) 770 (76.1%)
Age, years, median
(range)
54.3
(18.2e91.1)
56.8
(18.2e91.1)
48.5
(25e83)
60.1
(25.4e84.2)
54.9
(19e81.4)
56.1
(18.9e67.7)
53.1
(18.9e67.7)
48.1
(25.7e59.1)
57.8
(21.4e44.1)
Male 423 (39.2%) 236 (56.6%) 4 (1.2%) 82 (67.2%) 101 (48.3%) 555 (54.8%) 77 (62.6%) 1 (0.8%) 477 (61.9%)
Comorbidities
Diabetes 87 (8.0%) 38 (9.1%) 8 (2.4%) 23 (18.9%) 18 (8.6%) 106 (10.5%) 11 (8.9%) 3 (2.5%) 92 (11.9)
Hypertension 114 (10.6%) 47 (11.2%) 13 (4%) 31 (25.4%) 23 (11%) 132 (13%) 17 (13.8%) 2 (1.7%) 113 (14.7%)
History of previous
tuberculosis
37 (3.4%) 20 (4.8%) 2 (0.6%) 11 (9.0%) 4 (1.9%) 42 (4.2%) 12 (9.8%) 1 (0.8%) 29 (3.8%)
COPD, asthma 11 (1.0%) 7 (1.7%) 0 2 (1.6%) 2 (1.0%) 22 (2.2%) 2 (1.6%) 1 (0.8%) 19 (2.5%)
Cardiovascular
diseases
43 (3.9%) 23 (5.5%) 9 (2.7%) 7 (5.5%) 4 (1.9%) 31 (3.1%) 4 (3.2%) 1 (0.8%) 26 (3.4%)
Indication for e mAb use
Lymphoma 418 (38.8%) 418 (100%) 0 0 0 123 (12.4%) 123 (100%) 0 0
Gastric cancer 25 (2.3%) 0 6 (1.7%) 7 (5.7%) 12 (5.7%) 194 (19.2%) 0 0 194 (25.2%)
Colorectal cancer 187 (17.3%) 0 0 84 (68.9%) 103 (49.2%) 528 (52.2%) 0 0 528 (68.6%)
Breast cancer 355 (32.9%) 0 320 (97.3%) 1 (0.8%) 34 (16.2%) 129 (12.7%) 0 119 (100%) 10 (1.3%)
Lung cancer 13 (1.2%) 0 0 3 (2.5%) 10 (3.4%) 12 (1.2%) 0 0 12 (1.6%)
Head and neck 51 (4.7%) 0 0 22 (18%) 29 (13.9%) 26 (2.6%) 0 0 26 (3.4%)
Regimen
mAb only
regimen
184 (17.1%) 27 (6.5%) 126 (38.3%) 27 (22.1%) 4 (1.9%)
Progression
disease
588(54.5%) 117 (28%) 162 (49.2%) 122 (100%) 187 (89.5%) 879 (86.8%) 78 (63.4%) 118 (99.2%) 683 (88.7%)
CHOP, cyclophosphamide, adriamycin, vincristine, and prednisolonm; FOLFOX, oxaliplatin, leucovorin, and 5-fluorouracil; FOLFIRI, irinotecan, leucovorin, and 5-fluorouracil.
A
d
ve
rse
p
u
lm
o
n
a
ry
re
a
ctio
n
s
in
ca
n
ce
r
p
a
tie
n
ts
445
Table 2 Clinical characteristics of the adverse pulmonary reactions associated with the use of targeted chemotherapeutic agents.
Users of targeted chemotherapeutic agents Non-users of targeted chemotherapeutic agents
Total
(NZ 1078)
Rituximab
(NZ 418)
Trastuzumab
(NZ 329)
Cetuximab
(NZ 122)
Bevacizumab
(NZ 209)
Total
(NZ 1012)
CHOP (counterpart
of rituximab user)
(NZ 123)
Taxol (counterpart
of trastuzumab
user) (NZ 119)
FOLFOX or FOLFIRI
(counterpart of
cetuximab /
bevacizumab user)
(NZ 770)
Total pulmonary
complication
36 (3.5%) 22 (5.3%) 2 (0.6%) 11 (9%) 1 (0.5%) 28 (2.8%) 13 (10.6%) 2 (1.7%) 13 (1.7%)
Non-infectious
complications
8 (0.7%) 7 (1.7%) 1 (0.3%) 0 (0%) 0 (0%) 2 (0.2%) 1 (0.8%) 0 (0%) 1 (0.1%)
Hypersensitivity with
bronchospasm
2 1 1 0 0 0 0 0 0
Drug-induced interstitial
lung disease
6 6 0 0 0 2 1 0 1
Infectious complications 28 (2.8%) 15 (3.6%) 1 (0.3%) 11 (9%) 1 (0.5%) 26 (2.6%) 12 (9.8%) 2 (1.7%) 12 (1.6%)
Indication for -mAb use
Lymphoma 22 22 0 0 0 13 13 0 0
Colorectal cancer 7 0 0 6 1 6 0 0 6
Gastric cancer 0 0 0 0 0 7 0 0 7
Breast cancer 3 0 2 1 0 2 0 2 0
Lung cancer 2 0 0 2 0 0 0 0 0
Head and neck 2 0 0 2 0 0 0 0 0
Laboratory test resulta
Non-infectious complications
Leukocytes(103/ml) 8.56 8.67 7.8 3.56 3.11 4
CRP (mg/dL) 4.67 3.93 9.18 1.85 1.5 2.2
Infectious complications
Leukocytes (103/ml) 10.12 7.7 17.8 11.97 8.56 8.25 5.56 6.45 11.02
CRP (mg/dL) 12.02 11.79 15.72 12.07 10.3 14.55 6.65 10.11 20.34
Cancer stage
IeIII 13 13 0 0 0 4 1 0 3
IV 23 9 2 11 1 24 12 2 10
Regimen
mAb only (nZ 184) 7 1 2 4 0
Combination 29 R-CHOP 18
R-CVP 2
R-ICE 1
0 C-Irinotecan 2
C-FOLFOX 1
C-FOLFIRI 1
C-Xeloda 1
C-TS/CDDP 1
C-Docetaxel 1
B-FOLFIRI 1
446
H
.J.
K
a
n
g
e
t
a
l.
P
e
rf
o
rm
a
n
ce
st
a
tu
s
(E
C
O
G
)
0e
1
20
17
0
3
0
16
10
2
4
2
15
5
2
7
1
12
3
0
9
3e
4
1
0
0
1
0
0
0
0
0
M
e
d
ia
n
n
u
m
b
e
r
o
f
cy
cl
e
s
to
co
m
p
li
ca
ti
o
n
(r
a
n
ge
)
2.
97
(1
e
8)
3.
4
(1
e
8)
1.
5
(1
e
2)
2.
6
(1
e
4)
1
3.
95
(1
e
13
)
2.
9
(1
e
6)
2
(1
e
3)
9.
8
(1
e
13
)
1
st
li
n
e
ch
e
m
o
th
e
ra
p
y
21
19
0
1
1
13
6
0
7
2n
d
li
n
e
ch
e
m
o
th
e
ra
p
y
3
1
0
2
0
9
4
0
5
3
rd
li
n
e
ch
e
m
o
th
e
ra
p
y
12
2
2
8
0
6
3
2
1
C
R
P,
C
-r
e
a
ct
iv
e
p
ro
te
in
;
R
-C
H
O
P,
R
it
u
xi
m
a
b
,
cy
cl
o
p
h
o
sp
h
a
m
id
e
,
a
d
ri
am
yc
in
,
vi
n
cr
is
ti
n
e
,
a
n
d
p
re
d
n
is
o
lo
n
m
;
R
-I
C
E
,
R
it
u
xi
m
a
b
,
if
o
sf
a
m
id
e
,
ca
rb
o
p
la
ti
n
,
a
n
d
e
to
p
o
si
d
e
;
R
-C
V
P,
R
it
u
xi
m
a
b
,
cy
cl
o
p
h
o
sp
h
a
m
id
e
,
vi
n
cr
is
ti
n
e
,
a
n
d
p
re
d
n
is
o
lo
n
e
;
C
-F
O
LF
O
X
,
C
e
tu
xi
m
a
b
,
o
xa
li
p
la
ti
n
,
le
u
co
vo
ri
n
,
a
n
d
5-
fl
u
o
ro
u
ra
ci
l;
C
-F
O
LF
IR
I,
C
e
tu
xi
m
a
b
,
ir
in
o
te
ca
n
,
le
u
co
vo
ri
n
,
a
n
d
5-
fl
u
o
ro
u
ra
ci
l;
C
-
T
S/
C
D
D
P,
C
e
tu
xi
m
a
b
,
T
S-
1,
a
n
d
ci
sp
la
ti
n
;
B
-F
O
LF
IR
I,
B
e
va
ci
zu
m
a
b
,
ir
in
o
te
ca
n
,
le
u
co
vo
ri
n
,
a
n
d
5-
fl
u
o
ro
u
ra
ci
l.
a
A
t
o
cc
u
rr
e
n
ce
o
f
a
d
ve
rs
e
p
u
lm
o
n
a
ry
re
ac
ti
o
n
s.
Adverse pulmonary reactions in cancer patients 447- At least one systemic feature (either a symptom
complex of sweating, fever, shivering, aches, and
pains and/or temperature of 38 C or more).
- No other explanation for the illness, which was
treated with antibiotics as community acquired
pneumonia.12,13Statistical analysis
The baseline characteristics of patients were expressed as
median values with interquartile ranges (IQR) or mean-
s standard deviation (SD). Univariable analysis was per-
formed to identify risk factors for pulmonary complication
associated with anticancer chemotherapy including mono-
clonal antibodies. Between the groups with pulmonary
adverse reaction group and the non-pulmonary complica-
tion group, comparisons of demographic characteristics,
laboratory results, and treatment outcomes were per-
formed using Pearson’s c2 test or Fisher’s exact test for
categorical variables and Student’s t test for continuous
variables. Multivariable analysis was performed using the
logistic regression procedure to assess the relationship
between several factors and the onset of pulmonary
complication. P values less than 0.05 were considered
statistically significant. All statistical analyses were per-
formed with SPSS software (version 17.0, Chicago, IL, USA)
Results
Patient baseline characteristics
In total, 1078 patients were included in the analysis (418 for
rituximab, 329 for trastuzumab, 122 for cetuximab, 209 for
bevacizumab). Their median agewas 54.3 (range, 18.2e91.1
years), and 39.2% were males. Rituximab was used only for
patients with lymphoma, trastuzumab for those with breast
cancer, cetuximab for colorectal and head and neck cancers,
and bevacizumab for colorectal, breast, and head and neck
cancers. In total, 184 (17.1%) patients received mAb
chemotherapy as monotherapy (Table 1).
As a comparison group, a total of 1012 patients treated
during study period were included: 123 CHOP users, 119
Taxol users, and 770 FOLFOX or FOLFIRI users (Table 1).
Incidence of pulmonary adverse reaction
Of the 1078 patients, adverse pulmonary reactions were
identified in 36 (3.5%). The incidence differed among the
agents: cetuximab (11/122, 9%), rituximab (22/418, 5.3%),
trastuzumab (2/329, 0.6%), bevacizumab (1/209, 0.5%).
Infectious pulmonary complications occurred in 28
patients, and eight patients experienced non-infectious
pulmonary complications. Pneumonia developed in two
out of three lung cancer patients on cetuximab. Six of these
eight patients were diagnosed with interstitial lung disease
and two with acute hypersensitivity and bronchospasm
during infusion of mAbs. Interstitial lung disease was diag-
nosed through thoracoscopic surgical biopsy in one patient.
Diffuse thickening and fibrosis of alveolar septal wall was
448 H.J. Kang et al.the major pathologic finding. The other five patients were
diagnosed based on clinical and radiographic findings.
Dyspnea was the most common symptom and diffuse
ground-glass opacities were observed most frequently on
their computed tomography of the chest. The median
number of cycles of mAb treatment prior to the adverse
pulmonary reactions was three. The incidence of adverse
pulmonary reactions in patients treated only with a mAb
regimen did not differ from all patients (7/184, 3.8%;
PZ 0.655) (Table 2).
Among 1012 patient in the comparison groups, 28 (2.8%)
patients experienced adverse pulmonary reactions. It was
not different from that of 1078 patients (3.5%) treated with
comparable regimens with monoclonal antibodies
(PZ 0.53). However, incidence of adverse pulmonary
reaction was higher among cetuximab users than counter-
part group (9% vs. 1.7%, P< 0.001), mainly from higher rate
of infectious complications (Table 2).
Evolution of pulmonary adverse reaction
Ten of the 28 patients with pneumonia as a pulmonary
adverse reaction from the mAbs improved with the use of
antimicrobials. Despite meticulous use of wide-spectrum
antibodies, pneumonia aggravation caused death in theTable 3 Univariate analysis of risk factors for adverse pulmona
Number of subjects Pulmonary ad
No (NZ 1042
Age, years, median (range) 54.09 13.50
Body mass index, kg/m2 22.50 3.18
Sex (male) 408 (39.2%)
mAb only regimen 177 (17.0%)
Another mAb use history 41 (3.9%)
Current/ex smoking 57/1033a (5.5
Comorbidities
Diabetes 81 (7.8%)
Hypertension 111 (10.7%)
History of previous tuberculosis 34 (3.3%)
COPD, Asthma 11 (1.1%)
Other malignancy 52 (5.0%)
Chronic kidney disease 12 (1.2%)
Cardiovascular diseases 40 (3.8%)
Laboratory test result at 1st chemotherapy
Hemoglobin (g/dL) 12.13 1.80
Leukocytes (103/ml) 6.40 4.26
Platelet (103/ml) 227.65 102.
BUN (mg/dL) 15.93 70.07
Serum creatinine (mg/dL) 0.98 0.85
AST (IU/L) 35.56 60.92
ALT (IU/L) 30.23 44.44
Total bilirubin (mg/dL) 0.85 2.50
Alkaline phosphatase (IU/L) 107.24 97.3
Albumin (g/dL) 3.99 2.19
Data are presented as mean standard deviation or n (%), unless oth
a Number of available data.
b Data used for multivariable analysis.other 18 patients. All eight patients with non-infectious
adverse reactions improved. Four of them were adminis-
tered 0.5e1 mg/kg/day methylprednisolone for several
days.
Risk factors of pulmonary adverse reaction
Male gender and a history of smoking were more common in
patients with adverse pulmonary reactions (Table 3).
However, only low serum albumin level was associated with
the development of adverse pulmonary reactions after
adjusting for other variables (odds ratio, 0.32; 95% confi-
dence interval, 0.182e0.561). The fitness of this model was
confirmed with the HosmereLemeshow goodness of fitness
test (PZ 0.173; Table 4).
Discussion
Despite an explosion in the number of available molecular-
targeted agents, limited data exists regarding adverse
events associated with their use.4 Drug-associated lung
injury results either from cellular dysfunction, which
induces apoptosis, or by impairing the cell and tissue repair
sequence.2 For example, EGFR is expressed on type IIry reaction.
verse reaction P value
) Yes (NZ 36)
57.15 20.63 0.192b
21.36 5.38 0.214
22 (61.1%) 0.014b
7 (19.4%) 0.665
1 (2.8%) 1.000
%) 6/36a (16.7%) 0.049b
6 (16.7%) 0.063b
3 (8.3%) 1.000
3 (8.3%) 0.123b
0 (0%) 1.000
2 (5.6%) 0.701
0 (0%) 1.000
0 (0%) 0.64
11.55 1.90 0.059b
7.45 5.65 0.149b
15 252.58 127.72 0.254
14.77 7.93 0.922
2.097 6.68 0.322
32.08 14.85 0.733
25.60 25.52 0.535
3.66 15.50 0.286
5 126.11 110.19 0.255
3.41 0.64 0.108b
erwise stated.
Table 4 Multivariate analysis of risk factors for adverse pulmonary reaction risk factors.a
Variables Adjusted
odds ratio
95% Confidence
interval
P value
Age, years, median (range)b 1.008 0.980e1.036 0.587
Sex 0.663f 0.312e1.412 0.287
Current/ex-smoking 2.031 0.839e4.918 0.116
Diabetes 1.835 0.704e4.787 0.214
History of previous tuberculosis 2.337 0.641e8.517 0.198
Hemoglobin (g/dL)c 0.990 0.817e1.199 0.916
Leukocyte (103/ml)d 1.000 1.000e1.000 0.855
Albumin (g/dL)e 0.320 0.182e0.561 <0.001
a HosmereLemeshow goodness of fit (GOF) : P value 0.173.
b (xþ 1 years vs. x years).
c (xþ 1 g/dL vs. x g/dL).
d (xþ 1 103/ml vs. x 103/ml).
e (xþ 1 g/dL vs. x g/dL).
f Odds ratio for female/male.
Adverse pulmonary reactions in cancer patients 449pneumocytes, which are involved in alveolar wall repair.
Thus, agents targeting the EGFR, such as cetuximab, may
impair alveolar repair mechanisms.14,15 Another process
that is likely involved is angiogenesis, which plays a key role
in wound healing. Mediators of wound angiogenesis, such as
vascular endothelial growth factor (VEGF), have been
identified in several wound healing models. Bevacizumab,
which blocks the VEGF receptor, could inhibit the wound
healing process during recovery from a lung injury.16,17
We identified 36 (3.5%) of the 1078 patients with cancer
who developed adverse pulmonary reactions during or after
treatment with a regimen that included mAbs. Pneumonia
occurred in 28 patients, and eight patients experienced
non-infectious pulmonary complications, most commonly,
interstitial lung disease (6 patients).
The incidence of adverse pulmonary reactions in our
patients was quite similar to that in previous studies.
Previous studies reported that rituximab-induced intersti-
tial lung disease (ILD) at <0.03%.6,8,9 In our study, the
incidence of rituximab-ILD was 1.4%. In our study, adverse
pulmonary reactions were rare among patients treated with
trastuzumab (0.6%) and it was similar to other studies
(0.4e9.6%).18e20 However, the incidence of adverse
pulmonary reactions in cetuximab users in our study (9%)
seemed to be higher than reported rates (3.4%) from
cetuximab users with colorectal cancers.7 In fact, the
incidence of adverse pulmonary reaction was higher among
cetuximab users than their counterpart group (9% vs. 1.7%,
P< 0.001), in our study. The reason why cetuximab users in
our cohort were more susceptible to adverse pulmonary
reaction than others should be determined through future
studies.
Low albumin level was identified as a risk factor for
developing an adverse pulmonary reaction in this study.
Low albumin level is a strong risk factor for patients who
are admitted to the hospital with pneumonia after
discharge.21,22 Poor nutritional status, as evidenced by low
cholesterol, hypo-albuminemia, and low body weight due
to chronic or severe malnutrition, is an important risk
factor for pneumonia.23 Because pneumonia was the most
common adverse event in this study, a lower albumin levelcould be a risk factor for developing adverse pulmonary
events.
In conclusion, infectious and non-infectious adverse
pulmonary reactions occur in patients with cancer who are
administered a regimen including monoclonal antibodies.
Clinicians should be alert for the possibility of adverse
pulmonary reactions, particularly among patients with
a low serum albumin level.
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